Long-term safety of risperidone

M. Davidson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day). During 12-month, open-label extensions to these studies, the incidence of de novo tardive dyskinesia was very low. No clinically significant adverse events, changes in vital signs, or laboratory signs were observed. In summary, the safety and tolerability of risperidone in treating elderly dementia sufferers has been favorable in several clinical trials.

Original languageEnglish
Pages (from-to)26-28
Number of pages3
JournalJournal of Clinical Psychiatry
Volume62
Issue numberSUPPL. 22
StatePublished - 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Long-term safety of risperidone'. Together they form a unique fingerprint.

Cite this